EYPT is now on another breakout on the 2h chart similar to what occurred
from mid-December to mid-January. On the indicators the MACD shows
the K/D lines on a steep upward slope. For me, what set off my interest
was a relative volume scan that produced this stock on the list.
The relative volume this week and consequential accumulation triggered
the...
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for...
BREAKOUT STOCK ALERT UPDATE
$EYPT - EyePoint Pharmaceuticals, Inc. - Common Stock Status Alert: Deficient
Initial Alert Price: $4.78
Price High: $6.23
% Gains/Losses: 30.33%
(+19.33% More Than Expected)
Potential Stop Loss: $5.92
EYPT hit $6.17 after retesting the $5.29 Levels as we predicted hitting its 52-Wk High. The stock looks like it may be falling back...
I’m sharing this as an impromptu for this upcoming weeks Earnings regarding what stock looks like pre-R/S, being this severely damaged. I look forward to seeing how management goes forward with addressing the company’s current financial state.
Technicals :
- Stock at bottom of wedge = Bullish, for bounce play, especially “good” on news.
- Weekly RSI...
EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements
the expansion of their exclusive license agreements for the development and commercialization of YUTIQ® and DEXYCU® in certain Asian markets.
Ocumension has made a one-time $9.5 million payment to EyePoint for rights to commercialize both...
EYPT: EyePoint Pharmaceuticals, Inc.
2020-03-02 07:00:10
EyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ®
EYPT chart is building up for another run. Potential catalyst before year end with an sNDA for Short Duration Yutiq. accumulation has been slow and steady indicating EYPT oversold conditions.
Technical's:
weekly chart --> Harmonic Gartley (bounced off significant support level) and been in uptrend since.
Symmetrical Triangle/ Breakout setup has been known...
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
SHORT INTEREST
5.18M...
Long-Term pattern suggests that after previous dilution, Eyepoint's stock price went range bound for quite awhile before breaking out.
This marks potential accumulation range for anyone looking to build a position in EYPT.
Ranges make for good swing trade positions (especially 20%+ both ways) and a way to average down.
Range low/ highs, range from $1.42 -...
Eyepoint pharmaceuticals today was added to the Russell 2000 and 3000. The pharmaceutical company has alot to prove this quarter with regards to their loan with CRG, but a earnings beat would spark investor/ hedge fund investment which could give potential massive upside for EYPT and current investors.
Why EYPT
After EYPT diluted (one of EYPT's pain points) more...
